Skip to main content

Advertisement

SpringerLink
Log in

Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

To perform a health economic analysis on treatment with irbesartan in patients with type 2 diabetes and hypertension. A Markov model was adapted to the Hungarian setting to simulate renal deterioration from the development of microalbuminuria to nephropathy, doubling of serum creatinine, end-stage renal disease (ESRD) and all-cause mortality. Outcomes for two treatments were evaluated: (1) a placebo regimen of standard antihypertensive medications, and (2) the addition of irbesartan 300 mg administered daily, with both treatment initiated after developing microalbuminuria. Outcomes were discounted at 5% annually to correspond with national guidelines. Treatment with irbesartan was estimated to improve undiscounted life expectancy by 0.98 ± 0.05 years, reduce the cumulative incidence of ESRD by 7.5 ± 0.4%, and reduce lifetime costs by Hungarian Forints (HUF) 519,993 ± 70,814, compared to placebo. Irbesartan was projected to improved life expectancy and reduce costs compared to placebo in the Hungarian setting in hypertensive patients with type 2 diabetes and microalbuminuria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ritz, E., Rychlik, I., Locatelli, F., Halimi, S.: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am. J. Kidney. Dis. 34(5), 795–808 (1999)

    Article  Google Scholar 

  2. Adeghate, E., Schattner, P., Peter, A., Dunn, E., Donath, T.: Diabetes mellitus and its complications in a Hungarian population. Arch. Physiol. Biochem. 109(3), 281–291 (2001)

    Article  Google Scholar 

  3. Molnar, M., Wittmann, I., Nagy, J.: Prevalence, course and risk factors of diabetic nephropathy in type-2 diabetes mellitus. Med. Sci. Monit. 6(5), 929–936 (2000)

    Google Scholar 

  4. Parving, H.H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S., Arner, P.: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med. 345(12), 910–912 (2001)

    Article  Google Scholar 

  5. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345(12), 851–860 (2001)

    Article  Google Scholar 

  6. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., et al.: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345(12), 861–869 (2001)

    Article  Google Scholar 

  7. Palmer, A.J., Annemans, L., Roze, S., Lamotte, M., Lapuerta, P., Chen, R., et al.: Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 27(8), 1897–1903 (2004)

    Article  Google Scholar 

  8. Gaede, P., Vedel, P., Larsen, N., Jensen, G.V., Parving, H.H., Pedersen, O.: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348(5), 383–393 (2003)

    Article  Google Scholar 

  9. World Health Organization. Life tables for 191 countries. World mortality in 2000. http://www.3.who.int/whosis/life_tables/life_tables.cfm?path=evidence, life_tables&language=english (2002)

  10. Stehouwer, C.D., Gall, M.A., Twisk, J.W., Knudsen, E., Emeis, J.J., Parving, H.H.: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51(4), 1157–1165 (2002)

    Article  Google Scholar 

  11. Briggs, A.H.: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17(5), 479–500 (2000)

    Article  Google Scholar 

  12. Járay, J., Kaló Z., Nagy, J.: Dialízis versus-vesetranszplantáció összehasonlító költséghatékonysági elemzés, Klinikai kiválóság. Springer, Heidelberg (1999)

  13. Adler, A.I., Stevens, R.J., Manley, S.E., Bilous, R.W., Cull, C.A., Holman, R.R.: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63(1), 225–232 (2003)

    Article  Google Scholar 

  14. Rodby, R.A., Chiou, C.F., Borenstein, J., Smitten, A., Sengupta, N., Palmer, A.J., et al.: The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin. Ther. 25(7), 2103–2119 (2003)

    Article  Google Scholar 

  15. Lacourciere, Y., Nadeau, A., Poirier, L., Tancrede, G.: Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 21(6 Pt 1), 786–794 (1993)

    Google Scholar 

  16. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V., et al.: Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int. Suppl. 45, S150–S155 (1994)

    Article  Google Scholar 

  17. Trevisan, R., Tiengo, A.: Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am. J. Hypertens 8(9), 876–883 (1995)

    Article  Google Scholar 

  18. Agardh, C.D., Garcia-Puig, J., Charbonnel, B., Angelkort, B., Barnett, A.H.: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J. Hum. Hypertens 10(3), 185–192 (1996)

    Google Scholar 

  19. Tatti, P., Pahor, M., Byington, R.P., Di Mauro, P., Guarisco, R., Strollo, G., et al.: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21(4), 597–603 (1998)

    Article  Google Scholar 

  20. Gaede, P., Vedel, P., Parving, H.H., Pedersen, O.: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomiised study. Lancet 353, 617–622 (1999)

    Article  Google Scholar 

  21. Chan, J.C., Ko, G.T., Leung, D.H., Cheung, R.C., Cheung, M.Y., So, W.Y., et al.: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 57(2), 590–600 (2000)

    Article  Google Scholar 

  22. Estacio, R.O., Jeffers, B.W., Gifford, N., Schrier, R.W.: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23(Suppl 2), B54–B64 (2000)

    Google Scholar 

Download references

Acknowledgments

This study was funded by an unrestricted grant from Sanofi-Aventis Hungary.

Author information

Authors and Affiliations

  1. CORE, Center for Outcomes Research, A Unit of IMS Health, Gewerbestrasse 25, 4123, Allschwil/Basel, Switzerland

    Andrew J. Palmer, William J. Valentine, Joshua A. Ray & Stephane Roze

  2. Medical and Health Science Center, School of Public Health, University of Debrecen, Debrecen, Hungary

    Noemi Muszbek

Authors
  1. Andrew J. Palmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William J. Valentine
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joshua A. Ray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephane Roze
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Noemi Muszbek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Palmer, A.J., Valentine, W.J., Ray, J.A. et al. Health economic implications of irbesartan treatment versus standard blood pressure control in patients with type 2 diabetes, hypertension and renal disease: a Hungarian analysis. Eur J Health Econ 8, 161–168 (2007). https://doi.org/10.1007/s10198-006-0033-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-006-0033-2

Keywords

Search

Navigation